DK2442791T3 - Former til dosering af apixaban - Google Patents
Former til dosering af apixaban Download PDFInfo
- Publication number
- DK2442791T3 DK2442791T3 DK10727611.5T DK10727611T DK2442791T3 DK 2442791 T3 DK2442791 T3 DK 2442791T3 DK 10727611 T DK10727611 T DK 10727611T DK 2442791 T3 DK2442791 T3 DK 2442791T3
- Authority
- DK
- Denmark
- Prior art keywords
- dosage forms
- apixaban
- apixaban dosage
- forms
- dosage
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title 1
- 229960003886 apixaban Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18744209P | 2009-06-16 | 2009-06-16 | |
| PCT/US2010/038660 WO2010147978A1 (en) | 2009-06-16 | 2010-06-15 | Dosage forms of apixaban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2442791T3 true DK2442791T3 (da) | 2020-03-02 |
Family
ID=42677548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10727611.5T DK2442791T3 (da) | 2009-06-16 | 2010-06-15 | Former til dosering af apixaban |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20120087978A1 (enExample) |
| EP (2) | EP2442791B1 (enExample) |
| JP (1) | JP5775071B2 (enExample) |
| KR (1) | KR20120029428A (enExample) |
| CN (1) | CN102802608A (enExample) |
| AU (1) | AU2010260208B2 (enExample) |
| BR (1) | BRPI1010739A2 (enExample) |
| CA (1) | CA2765413A1 (enExample) |
| CY (1) | CY1122685T1 (enExample) |
| DK (1) | DK2442791T3 (enExample) |
| ES (1) | ES2769357T3 (enExample) |
| HR (1) | HRP20200297T1 (enExample) |
| HU (1) | HUE048542T2 (enExample) |
| IL (1) | IL216421A0 (enExample) |
| LT (1) | LT2442791T (enExample) |
| MX (1) | MX2011013080A (enExample) |
| PL (1) | PL2442791T3 (enExample) |
| PT (1) | PT2442791T (enExample) |
| RU (1) | RU2012101214A (enExample) |
| SG (1) | SG176785A1 (enExample) |
| SI (1) | SI2442791T1 (enExample) |
| SM (1) | SMT202000093T1 (enExample) |
| WO (1) | WO2010147978A1 (enExample) |
| ZA (1) | ZA201109334B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309564A (en) | 2010-02-25 | 2024-02-01 | Pfizer | Preparations containing apixaban |
| US20120244222A1 (en) * | 2011-03-25 | 2012-09-27 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
| EP2554159A1 (en) | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| WO2013164839A2 (en) * | 2012-03-06 | 2013-11-07 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
| WO2013175494A2 (en) * | 2012-04-10 | 2013-11-28 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of direct thrombin inhibitors |
| EP2854759B1 (en) | 2012-05-24 | 2019-12-18 | ratiopharm GmbH | Dosage forms comprising apixaban and matrix former |
| US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
| RU2660358C2 (ru) * | 2012-09-26 | 2018-07-05 | Бристол-Майерс Сквибб Холдингс Айеленд | Жидкие лекарственные композиции апиксабана |
| CN104721156B (zh) * | 2013-12-18 | 2020-05-01 | 山东新时代药业有限公司 | 一种含利伐沙班的片剂 |
| CN105848644A (zh) * | 2013-12-23 | 2016-08-10 | 埃斯特韦实验室有限公司 | 经口药物组合物 |
| EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| CN104971355B (zh) * | 2014-04-02 | 2018-04-24 | 上海现代药物制剂工程研究中心有限公司 | 含有利伐沙班的组合物及其制备方法 |
| US20150335586A1 (en) | 2014-05-20 | 2015-11-26 | R.P. Scherer Technologies, Llc | Capsule dispensing container |
| JP6359390B2 (ja) * | 2014-09-05 | 2018-07-18 | テルモ株式会社 | インプラントデバイスおよびインプラントデバイス植え込み具 |
| WO2017088841A1 (en) | 2015-11-26 | 2017-06-01 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| CN106902115A (zh) * | 2015-12-22 | 2017-06-30 | 江苏万邦生化医药股份有限公司 | 阿哌沙班在治疗糖尿病足药物中的应用 |
| US10537524B2 (en) | 2016-01-12 | 2020-01-21 | North & South Brother Pharmacy Investment Company Limited | Apixaban solid composition and preparation method thereof |
| CN106986868B (zh) * | 2016-01-21 | 2020-04-21 | 广东东阳光药业有限公司 | 包含阿哌沙班的共晶体及其制备方法 |
| US11154558B2 (en) | 2016-04-15 | 2021-10-26 | Adams Pharmaceuticals LLC | Prevention of atherosclerotic events with direct factor Xa inhibitors |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
| CA3129056A1 (en) * | 2018-02-21 | 2019-08-29 | Aron H. BLAESI | Expanding structured dosage form |
| MX2020010673A (es) * | 2018-04-16 | 2020-10-28 | Bristol Myers Squibb Co | Formulaciones de apixaban. |
| KR20190130411A (ko) | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| WO2020034989A1 (zh) | 2018-08-14 | 2020-02-20 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
| CN109010273B (zh) * | 2018-10-08 | 2021-03-19 | 中国药科大学 | 一种阿哌沙班纳米混悬剂及其制备方法 |
| KR102045721B1 (ko) * | 2019-03-27 | 2019-11-18 | 주식회사 씨트리 | 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구 |
| KR102044676B1 (ko) * | 2019-03-27 | 2019-11-14 | 주식회사 씨트리 | 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법 |
| CN110037990B (zh) * | 2019-04-15 | 2023-03-28 | 海正药业(杭州)有限公司 | 一种阿哌沙班固体无定形分散体的制备工艺 |
| WO2020219384A1 (en) * | 2019-04-26 | 2020-10-29 | Taho Pharmaceuticals Ltd. | Apixaban transdermal delivery system and uses thereof |
| WO2020231791A1 (en) * | 2019-05-10 | 2020-11-19 | Fordoz Pharma Corp. | Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof |
| IL291452B1 (en) | 2019-09-18 | 2026-06-01 | Bristol Myers Squibb Co | Dosage forms for TYK2 inhibitors |
| JP7752487B2 (ja) * | 2020-03-24 | 2025-10-10 | 日本ジェネリック株式会社 | アピキサバン含有固体分散体 |
| JP7853532B2 (ja) | 2020-05-19 | 2026-04-30 | ファーマコスモス ホールディング エー／エス | 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物 |
| JP7520351B2 (ja) * | 2020-08-14 | 2024-07-23 | 日医工株式会社 | アピキサバン含有医薬組成物 |
| US20240325388A1 (en) * | 2020-09-18 | 2024-10-03 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CA3202161A1 (en) * | 2020-12-13 | 2022-06-16 | Matthaios VIDALIS | Liquid apixaban formulation in small dose volume |
| AU2022288053B2 (en) * | 2021-06-08 | 2025-08-07 | Taho Pharmaceuticals Ltd. | Apixaban film product and uses thereof |
| CN115715770B (zh) * | 2021-08-24 | 2024-01-26 | 新领医药技术(深圳)有限公司 | 阿哌沙班透皮贴剂及其制备方法 |
| US12213972B2 (en) * | 2022-07-27 | 2025-02-04 | Slayback Pharma Llc | Stable pharmaceutical compositions of apixaban |
| EP4642441A1 (en) * | 2022-12-26 | 2025-11-05 | Rexpharmatech Co., Ltd | Sustained-release tablet comprising apixaban |
| CN121358484A (zh) * | 2023-04-18 | 2026-01-16 | 因西克利克斯生物有限责任公司 | 用于施用inx-315的有利的人类剂量方案 |
| EP4731217A1 (en) * | 2023-06-23 | 2026-04-29 | Ronak Patel | A gastroretentive composition comprising apixaban |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4247498A (en) | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4564488A (en) | 1978-07-31 | 1986-01-14 | Akzo Nv | Methods for the preparation of porous fibers and membranes |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US4490431A (en) | 1982-11-03 | 1984-12-25 | Akzona Incorporated | 0.1 Micron rated polypropylene membrane and method for its preparation |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| US5225192A (en) | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5686133A (en) | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6492991B1 (en) | 1998-08-28 | 2002-12-10 | Ati International Srl | Method and apparatus for controlling compressed Z information in a video graphics system |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| DE69915346T2 (de) | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| ES2310164T3 (es) * | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| YU43702A (sh) | 1999-12-23 | 2004-11-25 | Pfizer Products Inc. | Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| OA12619A (en) | 2001-06-21 | 2006-06-12 | Pfizer Prod Inc | Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors. |
| EP1401503B1 (en) * | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
| KR100759635B1 (ko) | 2001-06-22 | 2007-09-17 | 화이자 프로덕츠 인코포레이티드 | 비정질 약물의 흡착체의 약학 조성물 |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
| PL372247A1 (en) | 2002-02-01 | 2005-07-11 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| BR0307332A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| TW200302748A (en) | 2002-02-01 | 2003-08-16 | Pfizer Prod Inc | Osmotic delivery system |
| CA2534371A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| GB0417132D0 (en) | 2004-07-31 | 2004-09-01 | Koninkl Philips Electronics Nv | A shift register circuit |
| US7396932B2 (en) | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| CN101340933A (zh) * | 2005-08-17 | 2009-01-07 | 百时美施贵宝公司 | 具有环糊精的因子xa抑制剂包合配合物 |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| US20070259913A1 (en) * | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
| US20090285887A1 (en) | 2006-09-12 | 2009-11-19 | Omar Abdelfattah Abu-Baker | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor |
| JPWO2008066102A1 (ja) | 2006-11-30 | 2010-03-11 | 武田薬品工業株式会社 | 徐放性製剤 |
-
2010
- 2010-06-14 SM SM20200093T patent/SMT202000093T1/it unknown
- 2010-06-15 WO PCT/US2010/038660 patent/WO2010147978A1/en not_active Ceased
- 2010-06-15 BR BRPI1010739A patent/BRPI1010739A2/pt not_active Application Discontinuation
- 2010-06-15 DK DK10727611.5T patent/DK2442791T3/da active
- 2010-06-15 HU HUE10727611A patent/HUE048542T2/hu unknown
- 2010-06-15 EP EP10727611.5A patent/EP2442791B1/en active Active
- 2010-06-15 HR HRP20200297TT patent/HRP20200297T1/hr unknown
- 2010-06-15 CA CA2765413A patent/CA2765413A1/en not_active Abandoned
- 2010-06-15 JP JP2012516197A patent/JP5775071B2/ja active Active
- 2010-06-15 LT LTEP10727611.5T patent/LT2442791T/lt unknown
- 2010-06-15 ES ES10727611T patent/ES2769357T3/es active Active
- 2010-06-15 SG SG2011091519A patent/SG176785A1/en unknown
- 2010-06-15 SI SI201031972T patent/SI2442791T1/sl unknown
- 2010-06-15 MX MX2011013080A patent/MX2011013080A/es not_active Application Discontinuation
- 2010-06-15 EP EP19158695.7A patent/EP3520776A1/en active Pending
- 2010-06-15 PL PL10727611T patent/PL2442791T3/pl unknown
- 2010-06-15 RU RU2012101214/15A patent/RU2012101214A/ru unknown
- 2010-06-15 PT PT107276115T patent/PT2442791T/pt unknown
- 2010-06-15 KR KR1020117030021A patent/KR20120029428A/ko not_active Withdrawn
- 2010-06-15 AU AU2010260208A patent/AU2010260208B2/en active Active
- 2010-06-15 CN CN2010800362888A patent/CN102802608A/zh active Pending
- 2010-06-15 US US13/378,236 patent/US20120087978A1/en not_active Abandoned
-
2011
- 2011-11-17 IL IL216421A patent/IL216421A0/en unknown
- 2011-12-19 ZA ZA2011/09334A patent/ZA201109334B/en unknown
-
2013
- 2013-07-02 US US13/933,718 patent/US20140030330A1/en not_active Abandoned
-
2014
- 2014-05-19 US US14/281,041 patent/US20140335178A1/en not_active Abandoned
-
2017
- 2017-03-30 US US15/474,296 patent/US20170202826A1/en not_active Abandoned
-
2020
- 2020-02-25 CY CY20201100172T patent/CY1122685T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201109334B (en) | 2014-05-28 |
| MX2011013080A (es) | 2012-01-20 |
| US20140030330A1 (en) | 2014-01-30 |
| SMT202000093T1 (it) | 2020-03-13 |
| ES2769357T3 (es) | 2020-06-25 |
| JP2012530141A (ja) | 2012-11-29 |
| AU2010260208B2 (en) | 2014-11-13 |
| BRPI1010739A2 (pt) | 2016-03-15 |
| US20120087978A1 (en) | 2012-04-12 |
| CY1122685T1 (el) | 2021-03-12 |
| EP3520776A1 (en) | 2019-08-07 |
| US20140335178A1 (en) | 2014-11-13 |
| EP2442791A1 (en) | 2012-04-25 |
| JP5775071B2 (ja) | 2015-09-09 |
| PL2442791T3 (pl) | 2020-05-18 |
| EP2442791B1 (en) | 2019-11-27 |
| LT2442791T (lt) | 2020-02-25 |
| CA2765413A1 (en) | 2010-12-23 |
| AU2010260208A1 (en) | 2011-12-15 |
| PT2442791T (pt) | 2020-02-06 |
| IL216421A0 (en) | 2012-02-29 |
| SG176785A1 (en) | 2012-01-30 |
| RU2012101214A (ru) | 2013-07-27 |
| US20170202826A1 (en) | 2017-07-20 |
| CN102802608A (zh) | 2012-11-28 |
| HRP20200297T1 (hr) | 2020-05-29 |
| ES2769357T8 (es) | 2020-08-06 |
| WO2010147978A1 (en) | 2010-12-23 |
| KR20120029428A (ko) | 2012-03-26 |
| HUE048542T2 (hu) | 2020-08-28 |
| SI2442791T1 (sl) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249285A0 (en) | Transaminase polypeptides | |
| BRPI1010739A2 (pt) | formas de dosagens de apixaban. | |
| DK2462134T3 (da) | N1-sulfonyl-5-fluorpyrimidinonderivater | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010004215A5 (de) | Hydrostataktor | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| EP2445547A4 (en) | CATHETERISM SYSTEM | |
| EP2491340A4 (en) | TELEMETRY PHOTOGRAPHIC APPARATUS | |
| EP2509489A4 (en) | SPRINKLER FOR EARLY HEEL REMOVAL | |
| EP2440486A4 (en) | CABLE RETRACTION SYSTEM | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| EP2440972A4 (en) | PROJECTION SYSTEM | |
| DE112010002728A5 (de) | Turboinhalator | |
| DE112010004249A5 (de) | Spindelaktor | |
| EP2446176A4 (en) | CYLINDER SEAL | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| DK2483126T3 (da) | Skinnekøretøj | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| DK2506968T3 (da) | Faujasit-zeolit | |
| EP2454221A4 (en) | cineole | |
| BRPI1010159A2 (pt) | bistuti | |
| EP2398476A4 (en) | Policosanol nanoparticles | |
| ITPD20090053U1 (it) | Paradordi per banchine | |
| BR112012003616A2 (pt) | metilpirroloprimidinacarboxamidas |